Journal Logo



Fuchs, K.1; Adriaans, A.1; Honders, W.1; van der Lee, D.1; van der Meijden, E.2; Pont, M.1, 3; Monajemi, R.4; Kielbasa, S.4; 't Hoen, P.5, 6; van Bergen, C.1; Falkenburg, F.1; Griffioen, M.1

doi: 10.1097/01.HS9.0000561840.42692.db
Simultaneous Sessions III: Stem cell transplantation - Experimental

1Department of Hematology, LUMC, Leiden, Netherlands

2Department of Internal Medicine, Hematology and Internal Oncology, University Hospital Erlangen, Erlangen, Germany

3Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, United States

4Department of Medical Statistics, LUMC, Leiden

5Centre for Molecular and Biomolecular Informatics, Radboud University Medical Center Nijmegen, Nijmegen

6Department of Human Genetics, LUMC, Leiden, Netherlands

Back to Top | Article Outline


Patients that undergo allogeneic stem cell transplantation (SCT) as treatment for hematological diseases face the risk of relapse as well as Graft-versus-Host Disease (GvHD). GvHD as well as the favorable Graft-versus-Leukemia effect are mediated by donor T cells. These T cells recognize minor histocompatibility antigens: polymorphic peptides, which are presented on the cell surface by HLA molecules and are caused by genetic differences in single nucleotide polymorphisms (SNPs) between patient and donor. Knowledge about mismatched minor histocompatibility antigens may enable a more directed donor search as well as better prediction and measurement of the Graft-versus-Leukemia effect and GvHD for personalized treatment after transplantation, thereby contributing to a better outcome for patients treated with allogeneic SCT.

Back to Top | Article Outline


Identification of minor histocompatibility antigens has been a laborious process in the past. Therefore, whole genome association scanning was developed in our laboratory. However, this method was restricted to two HLAs and screening of one million SNPs. The aim of this study is to develop and use an optimized method to identify the dominant repertoire of minor histocompatibility antigens in common HLA class I alleles.

Back to Top | Article Outline


Donor T-cells isolated from patients after allogeneic SCT are tested for recognition of a new panel of 191 selected B-cell lines, which are sequenced in the 1000 Genome Project. This panel enables the inclusion of seven common HLAs and increases SNP coverage to 12 million (MAF > 0.01). SNPs that strongly associate with T-cell recognition are subsequently validated to encode minor histocompatibility antigens.

Back to Top | Article Outline


A total of 19 novel minor histocompatibility antigens have been identified that are presented in seven common HLA class I alleles, showing the potential of this optimized approach. Besides conventional antigens, cryptic peptides were found as well as peptides restricted to HLAs that were not primarily targeted.

Back to Top | Article Outline


This improved approach for whole genome association scanning has been successfully applied in rapidly discovering new minor histocompatibility antigens. The new method surpasses previous methods in its rapidness and coverage of HLAs and SNPs across the human genome, which additionally allows for identification of cryptic peptides. With the increasing number of patients that are analyzed in this study, T-cells recognizing known minor histocompatibility antigens are more often isolated, indicating that the repertoire of minor histocompatibility antigens is limited. Our optimized method is expected to discover the majority of unknown antigens in this repertoire, thereby contributing essential knowledge for new strategies to improve clinical outcome after allogeneic SCT.

Copyright © 2019 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the European Hematology Association.